CAR-T cell

Phase 2Cell therapy

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

CAR-T cell is one of 231 small molecule programs targeting Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

230

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalignanciesRecruiting

Systemic Lupus ErythematosusActive, not recruiting

Solid Tumor MalignanciesRecruiting

Autoimmune DiseaseRecruiting

Acute Myeloid LeukemiaRecruiting

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Diffuse Large B-Cell LymphomaRecruiting

MalignanciesPhase 1

Recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Solid Tumor MalignanciesPhase 1

Recruiting

Autoimmune DiseasePhase 2

Recruiting

Acute Myeloid LeukemiaPhase 1

Recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Diffuse Large B-Cell LymphomaPhase 2

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

34 2

Xospata

Astellas

Phase 3

24 3

Fludara

Sanofi

Phase 3

17 4

Vepesid

AAvyxa

Phase 3

52 5

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 6

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 7

Vanflyta

Daiichi Sankyo

Phase 3

14 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Cellcept

Roche

Phase 3

10 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT04512716

Q4 2027

Phase 1Not yet recruiting

Autoimmune Disease

NCT06762119

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT06900764

Phase 1Recruiting

Malignancies

NCT07338604

Phase 1Recruiting

Solid Tumor Malignancies

NCT05003895

Q2 2028

Phase 1Not yet recruiting

Autoimmune Disease

NCT07040917

Clinical

Trials by Indication[1]

Autoimmune Disease3 trials

A Study of CAR-T Cells in Subjects With Autoimmune Diseases

Not yet recruiting·—·Phase 1·NCT07040917·12 enrolled

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT06685042·8 enrolled

A Study of CAR-T Cells in Subjects with Autoimmune Diseases

Not yet recruiting·ZZhejiang University·Phase 1·NCT06762119·6 enrolled

Malignancies2 trials

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04556266

Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Recruiting·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1·NCT07338604·15 enrolled

Recruiting·ZZhimin Zhai·Phase 1·NCT06642025·9 enrolled

5 more indications

Systemic Lupus Erythematosus1 trial

A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT06900764·24 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT06768905·30 enrolled

Malignancy1 trial

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Unknown status·SShanghai GeneChem Co., Ltd.·Phase 1/2·NCT02959151·20 enrolled

Solid Tumor Malignancies1 trial

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05003895·38 enrolled

B-cell acute lymphoblastic leukemia1 trial

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04512716·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for CAR-T cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PersonGen BioTherapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

CAR-T cell

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Autoimmune Disease3 trials

Malignancies2 trials

Nasopharyngeal Carcinoma1 trial

Lymphoblastic Lymphoma1 trial

Acute Myeloid Leukemia1 trial

Systemic Lupus Erythematosus1 trial

Diffuse Large B-Cell Lymphoma1 trial

Malignancy1 trial

Solid Tumor Malignancies1 trial

B-cell acute lymphoblastic leukemia1 trial

References

Drug Info

Quick Facts

Related News